Does low magnesium increase cardiac excitability and risk of supraventricular and ventricular arrhythmias?

Magnesium is a vital intracellular cation that serves as a cornerstone of cardiac electrophysiological stability. Low serum magnesium (hypomagnesemia) is a well-established driver of increased cardiac excitability and is clinically associated with a range of supraventricular and ventricular arrhythmias.

Mechanistic basis of excitability

The increase in cardiac excitability during magnesium deficiency stems from its role as an essential cofactor for the Na+/K+-ATPase pump and a regulator of ion channels:

• Resting potential instability: Hypomagnesemia impairs Na+/K+-ATPase activity, leading to partial depolarization of the resting membrane potential. This brings the cell closer to its firing threshold, making it more prone to premature activation.
• Potassium channel downregulation: Deficiency reduces the expression and function of crucial potassium channels, specifically Kir2.1 (IK1 current) and Kv4.2 (Ito current). This impairs the cell's ability to repolarize, prolonging the action potential duration and the QT interval.
• Calcium dysregulation: Magnesium acts as a natural calcium antagonist. Low levels increase inward calcium currents through L-type channels and promote diastolic calcium "leaks" from the sarcoplasmic reticulum via ryanodine receptors (RyR2), creating a substrate for triggered activity.

Clinical evidence for arrhythmias

Clinical data consistently link low magnesium to increased rhythmic instability:

• Ventricular arrhythmias: Robust evidence, including prospective studies and meta-analyses, shows an inverse relationship between serum magnesium and the risk of sudden cardiac death (SCD). In older populations, lower magnesium levels correlate with a higher burden of premature ventricular contractions (PVCs). In acute settings like myocardial infarction, hypomagnesemia is a predictor of ventricular tachycardia and fibrillation.
• Supraventricular arrhythmias: While data are more extensive for ventricular types, magnesium levels are significant for supraventricular tachycardia (SVT) and atrial fibrillation. Clinical management often includes magnesium supplementation to control heart rate and reduce recurrence in atrial fibrillation patients.

Bottom line

Low magnesium directly increases cardiac excitability by destabilizing the resting membrane potential and prolonging repolarization. This creates an electrophysiological environment highly susceptible to both supraventricular and ventricular arrhythmias, making magnesium monitoring a critical component of cardiovascular health management.